Russia to reduce dependence on API imported from India and China

27 May 2020

Russia plans to create conditions for the development of its own production of active pharmaceutical ingredients (APIs) within the next several years, which will allow the country to resolve its dependence on supplies from India and China, that have significantly declined since the beginning of the COVID-19 pandemic.

For this purpose, the government, together with some leading local producers, plan to create conditions for an increase of ingredients’ production to the figures of 1970s-1980s, when the domestic production completely covered the then Soviet Union needs for these products, reports The Pharma Letter’s local correspondent.

During the Soviet times, in addition to the development of domestic production, particular attention was paid to its development abroad.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK